3'-N-ACETYLNEURAMIN-LACTOSE SODIUM SALT
Modify Date: 2024-01-02 11:13:48
3'-N-ACETYLNEURAMIN-LACTOSE SODIUM SALT structure
|
Common Name | 3'-N-ACETYLNEURAMIN-LACTOSE SODIUM SALT | ||
|---|---|---|---|---|
| CAS Number | 128596-80-5 | Molecular Weight | 655.533 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C23H38NNaO19 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of 3'-N-ACETYLNEURAMIN-LACTOSE SODIUM SALT3'-Sialyllactose (3'-SL) sodium is a prebiotic, maintains immune homeostasis and exerts anti-inflammatory and anti-arthritic effects. 3'-Sialyllactose sodium is an ordinary carbohydrate with the lowest toxicity rating, it can be used for the research of inflammation[1][2][3]. |
| Name | Neu5Acα(2-3)Galβ(1-4)Glc Sodium Salt |
|---|---|
| Synonym | More Synonyms |
| Description | 3'-Sialyllactose (3'-SL) sodium is a prebiotic, maintains immune homeostasis and exerts anti-inflammatory and anti-arthritic effects. 3'-Sialyllactose sodium is an ordinary carbohydrate with the lowest toxicity rating, it can be used for the research of inflammation[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | 3'-Sialyllactose sodium (0-250 μM; 24-36 h) promotes and restores Col2a1 synthesis and accumulates extracellular sulphated proteoglycan, and inhibits the effect of inflammatory cytokines[1]. 3'-Sialyllactose sodium (0-250 μM; 24 h) activates the expression of Sox9 and inhibits NF-κB activation in chondrocytes[1]. 3'-Sialyllactose sodium (0-5000 μg/plate) shows no mutagenic effect with no evident growth inhibition and deposition in all strains in the presence or absence of metabolic activation[3]. 3'-Sialyllactose sodium (1250 μg/mL) induces no chromosomal aberrations and shows non-clastogenic effect in either the presence or absence of metabolic activation[3]. Western Blot Analysis[1] Cell Line: Chondrocytes Concentration: 0, 50, 100 and 250 μM Incubation Time: 24-36 hours Result: Dose-dependently increased Col2a1 transcript and protein levels, and restored Col2a1 expression in IL-1β-treated chondrocytes. Dose-dependently inhibited IL-1β-induced Mmp3, Mmp13 and Cox2 expression in chondrocytes. Reduced expression of Mmp3, Mmp13 and Cox2 induced by IL-6, IL-17 and TNF-α in chondrocytes. |
| In Vivo | 3'-Sialyllactose sodium (10-100 mg/kg; p.o. three times a week for 6 weeks) protects mice against cartilage destruction from osteoarthritis[1]. 3'-Sialyllactose sodium (500, 1000 and 2000 mg/kg; orally administration; once) induces no micronuclei in the bone marrow cells of mice[3]. 3'-Sialyllactose sodium (oral administration; (500 to 1000 to 2000 mg/kg) every dose at 4-day intervals) shows the maximum tolerance dose (MTD) is greater than 2000 mg/kg in male and female beagle dogs[3]. 3'-Sialyllactose sodium shows a lethal dose (LD50) above 20 g/kg bw, the highest dose tested[3]. Animal Model: 8-week-old male C57BL/6 mice with medial meniscus surgery[1] Dosage: 10, 50 and 100 mg/kg Administration: Oral gavage; 10-100 mg/kg three times a week; for 6 weeks Result: Effectively protected osteoarthritis mice against cartilage destruction by catabolic factor expression. |
| Molecular Formula | C23H38NNaO19 |
|---|---|
| Molecular Weight | 655.533 |
| Exact Mass | 655.193604 |
| PSA | 349.24000 |
| D-Glucose, O-5-(acetylamino)-3,5-dideoxy-D-glycero-α-D-galacto-2-nonulopyranonosyl-(2->3)-O-β-D-galactopyranosyl-(1->4)-, sodium salt (1:1) |
| 3'-Sialyllactose Sodium Salt |
| Sodium (6R)-5-acetamido-3,5-dideoxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]-β-L-threo-hex-2-ulopyranonosyl-(2->3)-β-D-galactopyranosyl-(1->4)-D-glucose |
| sodium,(2S,4S,5R,6R)-5-acetamido-2-[(2R,3S,4S,5R,6S)-3,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3R,4R,5R)-1,2,4,5-tetrahydroxy-6-oxohexan-3-yl]oxyoxan-4-yl]oxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylate |